News

An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team of researchers, including The University of Texas at Austin's Jason McLellan, report today in the journal Science that one dose of their vaccine candidate elicited large increases in RSV-neutralizing antibodies that were sustained for several months.

Until now, researchers haven't been able to accurately quantify a latent form of HIV that persists in patients' immune cells. This hampers doctors' ability to assess the effectiveness of a particular treatment and select better alternatives.

Last year, Texas saw a particularly deadly flu season. Now, there is a new Federal Drug Administration-approved treatment, Xofluza, designed to catch the flu in its early stages and stop it from spreading. The drug is thanks in large part to professor emeritus Robert Krug's basic research, undertaken almost 40 years ago.

From "Fantastic Voyage" to "Despicable Me," shrink rays have been a science-fiction staple on screen. Now chemists at The University of Texas at Austin have developed a real shrink ray that can change the size and shape of a block of gel-like material while human or bacterial cells grow on it. This new tool holds promise for biomedical researchers, including those seeking to shed light on how to grow replacement tissues and organs for implants.

Every year, millions of people have vacations and business trips ruined when they succumb to "traveler's diarrhea" during their journeys. A major cause of traveler's diarrhea is bacteria called Enterotoxigenic E. coli, or ETEC. A joint effort between scientists at the University of Georgia and the University of Texas at Austin has discovered what triggers ETEC to produce dangerous toxins in the body. They are using this information in an effort to develop a preventive vaccine for travelers.

In an era when for-profit companies collect a wealth of data about us, new research from The University of Texas at Austin shows that data collected by health care companies could — if made available to researchers and public health agencies — enable more accurate forecasts of when the next flu season will peak, how long it will last and how many people will get sick.

And other adventures in animal viruses teaching us about human disease.

This month marks the centennial of the first case of one of the world's deadliest flu outbreaks, which was reported on a Kansas army base. It is estimated that the 1918 flu infected 500 million people around the world and killed 50-100 million. With the 100^th anniversary, we sat down with graduate student Spencer Fox, who studies the flu virus and flu pandemics.

A discovery that Robert Krug, a University of Texas at Austin molecular biologist, made decades ago has led to the development of a new drug to fight flu infections more effectively than existing drug treatments.

Biologists at The University of Texas at Austin have developed a method for rapidly screening hundreds of thousands of potential drugs for fighting infections, an innovation that holds promise for combating the growing scourge of antibiotic-resistant bacteria. The method involves engineering bacteria to produce and test molecules that are potentially toxic to themselves.